Risk factor | Coefficient | SE | Hazard ratio (HR) | 95% confidence limits | p-value |
---|---|---|---|---|---|
Age under 40 | 0.085 | 0.122 | 1.09 | 0.86–1.38 | 0.486 |
Age (40–49) | −0.003 | 0.097 | 1.00 | 0.83–1.21 | 0.976 |
Age (50–59) |  |  | Ref |  |  |
Age (60–69) | −0.048 | 0.106 | 0.95 | 0.78–1.17 | 0.652 |
Age 70 & over | 0.388 | 0.104 | 1.47 | 1.20–1.81 | < 0.001 |
Tumour grade 1 | Â | Â | Ref | Â | Â |
Tumour grade 2 | 1.103 | 0.201 | 3.01 | 2.03–4.46 | < 0.001 |
Tumour grade 3 | 1.504 | 0.206 | 4.50 | 3.01–6.73 | < 0.001 |
Tumour size (0.1–19.9 mm) |  |  | Ref |  |  |
Tumour size (20–49.9 mm) | 0.734 | 0.088 | 2.08 | 1.75–2.48 | < 0.001 |
Tumour size (50 mm & more) | 1.047 | 0.118 | 2.85 | 2.26–3.59 | < 0.001 |
Positive lymph nodes (zero node) | Â | Â | Ref | Â | Â |
Positive lymph nodes (1–3 nodes) | 0.783 | 0.094 | 2.19 | 1.82–2.63 | < 0.001 |
Positive lymph nodes (4–9 nodes) | 1.277 | 0.106 | 3.59 | 2.92–4.41 | < 0.001 |
Positive lymph nodes (10 nodes & more) | 1.722 | 0.111 | 5.60 | 4.50–6.96 | < 0.001 |
Presence of metastases at diagnosis | 1.603 | 0.120 | 4.97 | 3.93–6.28 | < 0.001 |
No metastases at diagnosis | Â | Â | Ref | Â | Â |
Hormone receptor (1 negative & 1 positive) | 0.636 | 0.096 | 1.89 | 1.56–2.28 | < 0.001 |
Hormone receptor (double negative) | 1.023 | 0.091 | 2.78 | 2.33–3.32 | < 0.001 |
Hormone receptor (double positive) | Â | Â | Ref | Â | Â |
HER2 status (positive) | −0.206 | 0.094 | 0.81 | 0.68–0.98 | < 0.05 |
HER2 status (test not done) | 0.164 | 0.088 | 1.18 | 0.99–1.40 | 0.061 |
HER2 status (negative/equivocal) | Â | Â | Ref | Â | Â |
Lobular histological type of cancer | −0.046 | 0.121 | 0.95 | 0.75–1.21 | 0.702 |
Other histological type of cancer | −0.576 | 0.206 | 0.56 | 0.38–0.84 | < 0.01 |
Ductal histological type of cancer | Â | Â | Ref | Â | Â |
Maori | 0.121 | 0.121 | 1.13 | 0.89–1.43 | 0.316 |
Pacific | 0.007 | 0.118 | 1.01 | 0.80–1.27 | 0.949 |
Other | −0.518 | 0.124 | 0.60 | 0.47–0.76 | < 0.001 |
NZ European | Â | Â | Ref | Â | Â |